ITGAX and neoplasm: Surprisingly, SR9243 also reduced the population of tumor-resident polymorphonuclear MDSCs (PMN-MDSCs: CD11C + Ly6G + Ly6C-) (Fig. 5I,J), a central immune suppressive cell type known to underlie poor clinical outcomes and resistance to immunotherapy9,56,57.